On September 14, Eli Lilly rose 3.05% in regular trading, trading at approximately $1,135.78 per share, with turnover of $4.96 billion.

The gain comes as Eli Lilly officially completed its acquisition of AtaiBeckley, a clinical-stage biopharmaceutical company focused on developing rapid-acting neuroplastogens for mental health conditions. The deal, approved by AtaiBeckley shareholders at a special meeting, brings BPL-003 — an investigational program targeting treatment-resistant depression — into Eli Lilly's pipeline. The acquisition marks a significant expansion of the company's footprint in psychiatric therapeutics, a field with substantial unmet clinical need.

Separately, HSBC recently raised its price target on Eli Lilly to $940 from $850, while maintaining a Reduce rating. The analyst consensus remains overweight with a mean target of $1,352.49, suggesting broader Street confidence in the company's long-term growth trajectory. The AtaiBeckley deal adds to a series of recent strategic moves, including a planned $2.88 billion acquisition of Merida Biosciences and the FDA approval of Mounjaro for cardiovascular risk reduction in type 2 diabetes patients.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)